- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02307448
Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter randomized controlled trial, with a single-blind parallel design. 1,500 subjects are planned to enroll in the study. Each subject will be assigned to the treatments in random order. The stratified permuted block randomization method will be applied to the patient assignment. In addition to three study populations, i.e., DFU, VU and PU, and study centers, stratification will be based on one overall variable, (1) nutritional status (Low: Prealbumin <12mg/d vs. moderate: Prealbumin >= 12 mg/d) and one variable for each wound type. Diabetic food ulcer will be based on offloading (2a) (Specialty shoes vs. Total contact cast), pressure ulcer will be based on offloading (2b) (mattress vs. cushion), and venous leg ulcer will be based on compression (2c)(Low: <10 mmHG vs. High: >=30mmHG). Randomization will proceed within strata according to a permuted block scheme with a block size, or balancing interval, varying randomly between 2, 4 or 6. The primary endpoint will be evaluated by a blinded physician to avoid the bias.
Total duration of each patient in the study is expected to be 20 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- TriHealth Hatton Research Institute | Bethesda North Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
6.2 Inclusion Criteria
- Male or female ≥ 18 years of age.
- Wound must be diagnosed as Diabetic Foot Ulcers (DFU), Venous Ulcers (VU), or Pressure Ulcers (PU) with duration greater than 30 days at first visit/patient screening.
- If more than one non-healing wound is present, the largest wound will be selected and must be at least 2cm in size.
- Wound must be classified as Wagner 1 - 3 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
- There must be at least 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
- Wound must be clinically non-infected (A swab or deep tissue culture shall be performed at the discretion of the provider).
- If a female of childbearing potential, the patient must have a negative serum pregnancy test at screening.
- Patient has the capacity to understand and consent to be in the study. Written informed consent must be obtained from either the patient or the patient's legally acceptable representative prior to screening activities.
- Platelet count ≥ 75,000 (according to CBC)
- Hemoglobin (Hgb) level > 9 g/dL (according to CBC)
- Hematocrit (HCT or Ht) level > 27% (according to CBC)
- Ankle-Brachial Index (ABI) Test > 0.7
6.3 Exclusion Criteria
- Male or female <18 years of age
- Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, collagen, acid citrate dextrose solution A (ACDA).
- Wound is not a Diabetic Foot Ulcers (DFU), Venous Ulcer (VU), or Pressure Ulcer (PU) at duration of greater than 30 days at first visit/patient screening.
- Wounds smaller than 2cm will be excluded. Exclusion criteria do not include maximum wound size or age.
- Wound that is classified as Wagner 4 - 5 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
- There is less than 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
- Wound is clinically infected. (A swab or deep tissue culture shall be performed at the discretion of the provider).
- Presence of non-treated osteomyelitis.
- If female, patient is pregnant, nursing or plans to become pregnant during the duration of the trial.
- Patients who are cognitively impaired and do not have a healthcare proxy.
- Platelet count < 75,000 (according to CBC)
- Hemoglobin (Hgb) level ≤ 9 g/dL (according to CBC)
- Hematocrit (HCT or Ht) level ≤ 27% (according to CBC)
- Ankle-Brachial Index (ABI) Test ≤ 0.7
- Patient has lymphedema.
- Received electrostimulation, hyperbaric treatments, systemic corticosteroids, growth factors or any cell or tissue derived products for any wounds 30 days prior to entry into the study. (Except for patients receiving inhaled corticosteroid treatments for COPD)
- Received radiation therapy or chemotherapy within previous 3 months.
- Patient has inadequate venous access for repeated blood draw required for PRP preparation.
- Concurrent participation in a clinical trial in which an investigational agent is used.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PRP Group
Patients will receive weekly PRP treatments
|
Patients will receive weekly PRP treatments with standard of care.
Other Names:
|
Placebo Comparator: Standard of Care
Patients will receive weekly standard of care.
|
Patients will receive weekly standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound Closure
Time Frame: 20 weeks
|
The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment
|
20 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Louis Thibodeaux, MD,FACCWS, TriHealth Hatton Research Institute | Bethesda North Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10312014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pressure Ulcer
-
The Cleveland ClinicRecruitingStage 1 Pressure Ulcer | Stage 2 Pressure UlcerUnited States, Austria
-
University GhentCare of Sweden ABCompletedPressure Ulcer | Pressure Injury | Pressure Ulcer, Buttock | Pressure SoreBelgium
-
Our Lady of Maryknoll HospitalWong Tai Sin HospitalUnknownPressure Ulcers Stage III | Pressure Ulcer, Stage IVHong Kong
-
Integra LifeSciences CorporationSt Vincent's HospitalCompletedPressure Ulcer | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
ULURU Inc.United States Department of DefenseRecruitingPressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
Bayside HealthCompletedLength of ICU Stay | Pressure Ulcer, Area | Pressure Ulcer, Grade | Albumin Level | Risk ScoreAustralia
-
University of PittsburghUnited States Department of Defense; Georgia Institute of TechnologyCompletedPressure Ulcer | Pressure Injury | Pressure Ulcer, ButtockUnited States
-
Istanbul Medipol University HospitalCompletedPressure Ulcers Stage III | Pressure Ulcer, Stage IV
-
Istituto Ortopedico RizzoliCompleted
-
EmoledCompletedPressure Ulcer | Pressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure SoreItaly
Clinical Trials on Platelet Rich Plasma
-
Stanford UniversityPartnership for Clean CompetitionCompletedRheumatic Diseases | TendinopathyUnited States
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
Cardenal Herrera UniversityCompletedCarpal Tunnel SyndromeSpain
-
Damascus UniversityCompletedBone ResorptionSyrian Arab Republic
-
Peking University Third HospitalRecruiting
-
Rajavithi HospitalRecruitingAutologous Platelet-rich Plasma Supplement | Sperm Cryopreservation | Post-cryopreserved Sperm Quality | Semen AnalysisThailand
-
Matthew GettmanCompleted
-
Sutherland Medical CenterActive, not recruitingRotator Cuff Tears | Rotator Cuff TendinosisPoland
-
Skin Care and Laser Physicians of Beverly HillsEclipse Aesthetics, LLCUnknownAndrogenetic AlopeciaUnited States